Eli Lilly has begun construction on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley to produce injectable medicines, including the next-generation obesity treatment retatrutide. The site will create 850 high-wage jobs and about 2,000 construction jobs, supporting local economic growth. The facility will use advanced technologies like AI and digital automation to ensure high-quality production and aims for LEED Gold environmental certification. Operational by 2031, this investment is part of Lilly's $50 billion U.S. expansion to enhance medicine production and address major health challenges like obesity and diabetes.
Eli Lilly's stock trades at USD 1,436.72 on Pluang as of Nov 13, 2026 03:41 WIB, showing a slight 0.07% decline in one day. The company holds a market cap of $1.28 trillion, reflecting its significant presence in the health sector. Pluang investors show more buying interest with 63% of orders as Lilly expands its U.S. manufacturing footprint.
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Eli Lilly's TOGETHER-PsA Phase 3b trial showed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) nearly tripled the number of patients achieving at least 50% reduction in psoriatic arthritis (PsA) disease activity after one year compared t...
Hims & Hers reported a surprise Q3 loss and cut its full-year profit outlook, causing its stock to drop 18%. Despite 48.6% revenue growth, the company missed revenue estimates and faced margin pressure due to lower-margin weight-loss products and int...
Hims & Hers stock dropped 25.67% in a week following its deal with Eli Lilly to expand access to weight-loss drugs, despite Lilly's modest share gains. The decline reflects challenges from Hims' shift to branded GLP-1 drugs, including a drop in gross...
The FDA requires all makers of GLP-1 medications to add warnings about a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and possibly permanent vision loss. This decision follows a review of c...
